Savant Capital LLC Purchases 99 Shares of Becton, Dickinson and Company (BDX)

Savant Capital LLC boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 7.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,456 shares of the medical instruments supplier’s stock after purchasing an additional 99 shares during the quarter. Savant Capital LLC’s holdings in Becton, Dickinson and were worth $284,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. BlackRock Inc. raised its stake in Becton, Dickinson and by 2,427.8% in the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after purchasing an additional 15,887,611 shares during the last quarter. Vanguard Group Inc. raised its stake in Becton, Dickinson and by 5.3% in the 1st quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock valued at $2,917,094,000 after purchasing an additional 796,034 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Becton, Dickinson and by 6.5% in the 1st quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after purchasing an additional 242,081 shares during the last quarter. Wells Fargo & Company MN raised its stake in Becton, Dickinson and by 1.2% in the 1st quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock valued at $602,246,000 after purchasing an additional 39,362 shares during the last quarter. Finally, Fundsmith LLP raised its stake in Becton, Dickinson and by 3.2% in the 1st quarter. Fundsmith LLP now owns 2,296,613 shares of the medical instruments supplier’s stock valued at $421,291,000 after purchasing an additional 71,691 shares during the last quarter. 87.43% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company (BDX) opened at 197.58 on Friday. The stock’s 50 day moving average price is $199.61 and its 200-day moving average price is $191.24. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The stock has a market capitalization of $44.96 billion, a PE ratio of 57.22 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.35 earnings per share. Analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be issued a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.48%. Becton, Dickinson and’s payout ratio is currently 83.43%.

TRADEMARK VIOLATION WARNING: “Savant Capital LLC Purchases 99 Shares of Becton, Dickinson and Company (BDX)” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/09/15/savant-capital-llc-purchases-99-shares-of-becton-dickinson-and-company-bdx.html.

Several research analysts recently commented on BDX shares. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a research note on Monday, July 17th. Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and reduced their price objective for the company from $210.00 to $180.00 in a research note on Friday, June 30th. BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Cowen and Company reissued a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a research note on Monday, August 14th. Finally, Bank of America Corporation restated a “buy” rating and issued a $225.00 target price (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Becton, Dickinson and currently has an average rating of “Buy” and a consensus target price of $196.93.

In other news, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the sale, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the sale, the insider now owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. Insiders sold 75,904 shares of company stock valued at $15,242,688 in the last 90 days. Corporate insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply